Skip to main content
GoodMoatv1.3
Sign in
TECX logo

TECX

CompareEarnings: May 31, 2026

AvroBio Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Current Price

$28.53

-1.69%
Profile
Valuation (TTM)
Market Cap$543.15M
P/E-7.32
EV—
P/B2.16
Shares Out19.04M
P/Sales—
Revenue$0.00
EV/EBITDA—

AvroBio Inc (TECX) Company Profile

TECX Company Information

AVROBIO, Inc.

is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease.

The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring.

AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Massachusetts, USA

TECX Key Officers

Key officers data coming soon

TECX Company Profile

AvroBio Inc (TECX) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Massachusetts, USA.

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Market cap is $543.15M. There are 19.0M shares outstanding.

See the full AvroBio Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if TECX is a good investment.